sofosbuvir/velpatasvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 20 Diseases   29 Trials   29 Trials   1253 News 


«12345678910111213...1920»
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial part 2 (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1670;    
    Among inner city residents living with HCV infection, most of whom are active fentanyl users and unstably housed, the administration of S/V in the context of a robust program of engagement in care has led to HCV cure rates that exceed those achieved in clinical trials, with minimal opioid-related morbidity and loss to follow up within our system of care. The data we present validate the development of multidisciplinary programs as an important tool for HCV elimination in this vulnerable population.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    New tools reaching hepatitis C elimination: automatic hepatitis C virus detection in presurgical evaluations (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1632;    
    The data we present validate the development of multidisciplinary programs as an important tool for HCV elimination in this vulnerable population. These results demonstrate that the automation of the HCV serology testing in all patients who require blood work extractions, regardless of the reason and the medical unit that requests it, significantly increases the diagnosis of HCV.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan (Poster Area) -  Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_817;    
    An algorithm for simplified hepatitis C virus treatment with non-specialist care based on real-world data from a nationwide registry in Taiwan Background and Aims: Although pan-genotypic direct-acting antivirals (DAA) sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) have simplified hepatitis C virus (HCV) treatment, treatment access remains limited due to constraints of specialist resource (e.g., gastroenterologist). The TACR algorithm can provide important guidance in the effort to promote task sharing to non-specialists, which would be an important step towards HCV elimination.
  • ||||||||||  Simulect (basiliximab) / Novartis
    WHEN YOU DON'T HAVE ENOUGH: HEPATITIS C- VIRAEMIC DONOR TO A NAIVE RECIPIENT KIDNEY TRANSPLANTATION: THE FIRST IN MALAYSIA () -  Mar 28, 2023 - Abstract #ISNWCN2023ISN_WCN_1485;    
    Post transplantation on day two, he became viraemic with a HCV-RNA of 1.9LogIU/ml and was immediately initiated on Sofosbuvir/Velpatasvir 400mg/100mg...HCV can now be successfully treated with excellent outcomes and hence should not be a barrier in transplantation. Conclusions Hepatitis C infected patients should be accepted as potential donors be it living or deceased as treatment with DAA in Hepatitis C naive kidney recipients has been demonstrated to be effective and safe post transplantation.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal:  Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C. (Pubmed Central) -  Feb 22, 2023   
    P2
    Clinicians should have a deeper understanding of GADRs to improve the gastrointestinal tolerance of patients with chronic hepatitis C. Ledipasvir/sofosbuvir [and likely other direct-acting antivirals] is an effective treatment for HCV in the presence of PCT and leads to clinical remission of PCT without additional phlebotomy or low-dose hydroxychloroquine treatment.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal:  Hepatitis C micro-elimination through the retrieval strategy of patients lost to follow-up. (Pubmed Central) -  Feb 15, 2023   
    Ledipasvir/sofosbuvir [and likely other direct-acting antivirals] is an effective treatment for HCV in the presence of PCT and leads to clinical remission of PCT without additional phlebotomy or low-dose hydroxychloroquine treatment. Call back system can expand our reach to those unaware or ignoring chronic HCV infection patients and link them to treatment.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Sofosbuvir-based Regimen Achieved High Sustained Virological Response in Treatment Na (2nd floor Poster Area - 244) -  Feb 15, 2023 - Abstract #APASL2023APASL_870;    
    This real-world study showed that SOF-based regimens were well-tolerated with a cure rate (at SVR12) of 100%, in treatment-naive adolescent patients with chronic HCV infection with diverse genotypes especially GT1b or GT3b in China. 842
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Journal:  Modeling-Based Response-Guided Hepatitis C Treatment During Pregnancy and Postpartum. (Pubmed Central) -  Feb 14, 2023   
    Data from a 27-year-old woman indicated that, pretreatment, HCV was stable and that it dropped in a biphasic manner during sofosbuvir/velpatasvir therapy, reaching target not detected at time of delivery-16?days post-initiation of therapy. Mathematical modeling of measured HCV at days 0, 7, and 14 predicted that cure could have been achieved after 7?weeks of sofosbuvir/velpatasvir, reducing the duration of therapy by 5?weeks.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg.
    Trial completion date, Trial primary completion date:  THINKER-NEXT: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (clinicaltrials.gov) -  Feb 2, 2023   
    P2,  N=400, Recruiting, 
    Similar to that of placebo, SOF/VEL treatment of HCV infection had a safety/tolerability profile that was not affected by baseline factors, such as the presence of compensated cirrhosis, mild renal impairment, or advanced age. Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Jan 2025